These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 22580742)

  • 21. Parkinson's disease in the nuclear age of neuroinflammation.
    Nolan YM; Sullivan AM; Toulouse A
    Trends Mol Med; 2013 Mar; 19(3):187-96. PubMed ID: 23318001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease.
    Rosa AI; Duarte-Silva S; Silva-Fernandes A; Nunes MJ; Carvalho AN; Rodrigues E; Gama MJ; Rodrigues CMP; Maciel P; Castro-Caldas M
    Mol Neurobiol; 2018 Dec; 55(12):9139-9155. PubMed ID: 29651747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system.
    Vernier P; Moret F; Callier S; Snapyan M; Wersinger C; Sidhu A
    Ann N Y Acad Sci; 2004 Dec; 1035():231-49. PubMed ID: 15681811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomedicine. Combating Parkinson's disease--step three.
    Olson L
    Science; 2000 Oct; 290(5492):721-4. PubMed ID: 11184202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease.
    McCoy MK; Ruhn KA; Blesch A; Tansey MG
    Adv Exp Med Biol; 2011; 691():539-40. PubMed ID: 21153359
    [No Abstract]   [Full Text] [Related]  

  • 27. Neurotransmission in Parkinson's disease: beyond dopamine.
    Barone P
    Eur J Neurol; 2010 Mar; 17(3):364-76. PubMed ID: 20050885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
    McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
    J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.
    Collins LM; Toulouse A; Connor TJ; Nolan YM
    Neuropharmacology; 2012 Jun; 62(7):2154-68. PubMed ID: 22361232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine receptor agonists and sleep disturbances in Parkinson's disease.
    Chaudhuri KR; Logishetty K
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S101-4. PubMed ID: 20123546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self-perpetuating crosstalk?
    Vairetti M; Ferrigno A; Rizzo V; Ambrosi G; Bianchi A; Richelmi P; Blandini F; Armentero MT
    Biochim Biophys Acta; 2012 Feb; 1822(2):176-84. PubMed ID: 22119596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs.
    Bassani TB; Vital MA; Rauh LK
    Arq Neuropsiquiatr; 2015 Jul; 73(7):616-23. PubMed ID: 26200058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuron-Astrocyte Interactions in Parkinson's Disease.
    Miyazaki I; Asanuma M
    Cells; 2020 Dec; 9(12):. PubMed ID: 33297340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
    Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
    Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinson's disease and enhanced inflammatory response.
    Stojkovska I; Wagner BM; Morrison BE
    Exp Biol Med (Maywood); 2015 Nov; 240(11):1387-95. PubMed ID: 25769314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroimaging of nonmotor features of Parkinson's disease.
    Deblieck C; Wu AD
    Rev Neurol Dis; 2008; 5(3):125-33. PubMed ID: 18838952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol.
    Meredith GE; Totterdell S; Potashkin JA; Surmeier DJ
    Parkinsonism Relat Disord; 2008; 14 Suppl 2(Suppl 2):S112-5. PubMed ID: 18585085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease.
    Postuma RB; Gagnon JF; Vendette M; Montplaisir JY
    Brain; 2009 Dec; 132(Pt 12):3298-307. PubMed ID: 19843648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.